Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin

被引:38
作者
Eiling, S [1 ]
Lischner, S [1 ]
Busch, JO [1 ]
Rothaupt, D [1 ]
Christophers, E [1 ]
Hauschild, A [1 ]
机构
[1] Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany
关键词
angiosarcoma; liposomal doxorubicin; radio-resistant;
D O I
10.1046/j.1365-2133.2002.04726.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
We report an 80-year-old man suffering from an angiosarcoma of the scalp. Because of the wide extent of the lesions, surgery was not performed. Instead, the patient was treated with electron-beam radiation. Later, the patient failed to benefit from radiotherapy demonstrated by a local relapse and new malignant lesions. Additionally, a cervical lymph node metastasis appeared for the first time. Subsequently, we successfully administered liposomal doxorubicin (Caelyx((R)) ). Shortly after administration of two cycles the scalp angiosarcoma showed a clear regression. Following six cycles, the patient clinically showed a complete remission of all skin lesions and the cervical lymph node; metastasis was confirmed by histology and fine needle aspiration, respectively. Liposomal and pegylated doxorubicin, a cytostatic drug belonging to the anthracyclines, has already shown to be effective and mostly well tolerated in the therapy of acquired immune deficiency syndrome-related Kaposi's sarcoma and very recently in cutaneous T-cell lymphoma, too. Caelyx((R)) appears to be a promising alternative to conventional treatment of cutaneous angiosarcoma.
引用
收藏
页码:150 / 153
页数:4
相关论文
共 27 条
[1]   Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs [J].
Amantea, M ;
Newman, MS ;
Sullivan, TM ;
Forrest, A ;
Working, PK .
HUMAN & EXPERIMENTAL TOXICOLOGY, 1999, 18 (01) :17-26
[2]  
Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.3.CO
[3]  
2-G
[4]   Cutaneous angiosarcomas [J].
Fink-Puches, R ;
Smolle, J ;
Beham, A ;
Kerl, H ;
Soyer, HP .
HAUTARZT, 2000, 51 (07) :479-485
[5]  
GABZION A, 1997, DRUGS, V54, P15
[6]  
HENGGE UR, 1992, AIDS, V6, P35
[7]  
HOLDEN CA, 1987, CANCER, V59, P1046, DOI 10.1002/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO
[8]  
2-6
[9]   TREATMENT OF CUTANEOUS T-CELL LYMPHOMA WITH A COMBINATION OF LOW-DOSE INTERFERON ALFA-2B AND RETINOIDS [J].
KNOBLER, RM ;
TRAUTINGER, F ;
RADASZKIEWICZ, T ;
KOKOSCHKA, EM ;
MICKSCHE, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 24 (02) :247-252
[10]  
LIPPMAN SM, 1993, EUROP J CANC A, V29, P9